Reply: Niacin therapy improves outcome and normalizes metabolic abnormalities in an NAXD-deficient patient.

Van Bergen, Nicole J; Walvekar, Adhish S; Linster, Carole L; Christodoulou, John

Van Bergen, Nicole J; Walvekar, Adhish S; Linster, Carole L; Christodoulou, John.

Afiliação

Van Bergen NJ; Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia.
Walvekar AS; Department of Paediatrics, University of Melbourne, Melbourne, Australia.
Linster CL; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux L-4367, Luxembourg.
Christodoulou J; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux L-4367, Luxembourg.

Brain ; 145(5): e41-e42, 2022 06 03.

Article em En | MEDLINE | ID: mdl-35254397

Assuntos

Niacina; HDL-Colesterol; Humanos; Niacina/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Niacina Limite: Humans Idioma: En Revista: Brain Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google